TheraRadar
Data updated: May 26, 2026

RALDESY (trazodone hydrochloride)

CNS Approved 2024-11-26

Raldesy is an antidepressant used to help adults struggling with major depressive disorder. It helps patients manage the symptoms of clinical depression by altering chemical signaling within the brain. Healthcare providers prescribe this medication to improve mood and address the underlying biological factors associated with this condition.

Source: FDA Label • KAMAT

How RALDESY Works

This medication works by increasing the activity of serotonin within the central nervous system. It functions as both a selective serotonin reuptake inhibitor and a 5HT2 receptor antagonist, though the exact way these combined actions produce an antidepressant effect is not fully understood.

1
Indication
--
Phase 3 Trials
1
Years on Market

Details

Status
Prescription
First Approved
2024-11-26
Patent Cliff
2029

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
ORAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: TRAZODONE HYDROCHLORIDE

RALDESY Approval History

2025
2026
Original
New Indication
New Form
Label Update
3 FDA actions from 2024 to 2025
Nov 2025 SUPPL
Label · Labeling
Jun 2025 SUPPL
Label · Labeling
Nov 2024 ORIGINAL
New Form · Type 3 - New Dosage Form

What RALDESY Treats

1 indications

RALDESY is approved for 1 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Major Depressive Disorder
Source: FDA Label

RALDESY Boxed Warning

SUICIDAL THOUGHTS and BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . Trazodone is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )] . WARNING: SUICIDAL THOUGHTS and BEHAVIORS See full prescribing infor...

RALDESY Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 17 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to RALDESY

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

APLENZIN
BUPROPION HYDROBROMIDE
1 shared
BAUSCH
Shared indications:
AUVELITY
BUPROPION HYDROCHLORIDE
1 shared
AXSOME
Shared indications:
CAPLYTA
LUMATEPERONE TOSYLATE
1 shared
INTRA-CELLULAR
Shared indications:
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT06286189 2020P002760-t Ph 1, Ph 2 recruiting Trazodone on OSA Endotypes
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

RALDESY FDA Label Details

Indications & Usage

FDA Label (PDF)

RALDESY is indicated for the treatment of Major Depressive Disorder.

⚠️ BOXED WARNING

WARNING: SUICIDAL THOUGHTS and BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors...

View full patent landscape →
1 OB patents · 1 families · 59 international docs across 24 countries

RALDESY Patents & Exclusivity

Latest Patent: Mar 2029

Patents (1 active)

US8133893 Expires Mar 13, 2029
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for RALDESY

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2029
  • 1 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 20 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.